Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site

摘要: Background Hormone receptor and HER-2/neu discordance between the primary lesion first metastasis has been reported. This study was performed to determine further biomarker rates subsequent metastatic breast cancer lesions. Methods We a retrospective review of paired biomarkers from cancers compared reported metastases 103 patients with cancer. The estrogen (ER), progesterone (PR), status were at all three time points. In addition, hormone, cytotoxic, targeted treatments recorded for disease, survival determined. Results Between metastases, ER, PR, 15.8%, 33.7%, 14.3%, respectively. There second ER in 18.8%, PR 19.8%, 10.7%. Overall, there tumor either or 27.7%, 40.7%, 19.6% cases. Discordance affected survival, worse experienced by those hormone receptors remaining negative, intermediate discordant tumors (ER χ2=14.27, p=0.0008; χ2=11.31, p=0.0035). no difference whose discordant. Conclusion demonstrated that continued disease evolution may be associated different biology studies lesions appear warranted, especially if therapy is an option.